All Blog Posts | PerkinElmer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Expanding Your Assay Specificity: Cisbio Joins PerkinElmer

Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe.

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the AlphaLISA human PD-L1 assay.

New Earlier Screen For Pregnant Women

North York General Hospital researchers have developed an Enhanced First Trimester Screen that is faster, less costly, but just as accurate as the standard Integrated Prenatal Screening protocol in detecting the risk for Down syndrome and Trisomy 18. The new test was developed with the help of PerkinElmer and is now in use in Ontario, Canada.